Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 169
- Registration Number
- NCT02322814
- Locations
- 🇺🇸
Cancer Treatment Centers of America, Newnan, Georgia, United States
🇦🇺St John of God Murdoch Hospital; Oncology West, Murdoch, Western Australia, Australia
🇧🇪Clinique Edith Cavell, Bruxelles, Belgium
A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2020-08-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 221
- Registration Number
- NCT02323191
- Locations
- 🇺🇸
Dana Farber - Harvard, Boston, Massachusetts, United States
🇺🇸Memorial Sloan-Kettering Cancer Center Breast & Imaging Center, New York, New York, United States
🇪🇸Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain
Observational Safety Study of Rituximab in Patients Diagnosed With Rheumatoid Arthritis (RA) Who Did Not Respond Adequately to TNF-alpha Blocker
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 209
- Registration Number
- NCT02322801
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of RO6889678 and the Combination of RO6889678 With Ritonavir in Healthy Participants
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2014-12-22
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 100
- Registration Number
- NCT02321384
- Locations
- 🇳🇱
Centre For Human Drug Research; Research, Leiden, Netherlands
A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2014-12-19
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 154
- Registration Number
- NCT02320435
- Locations
- 🇧🇷
Núcleo de Pesquisa São Camilo, Sao Paulo, São Paulo, Brazil
🇧🇷Instituto Nacional de Cancer - INCa, Rio de Janeiro, Brazil
🇨🇳West China Hospital, Sichuan University, Chengdu, China
A Study of RO6927005 Either As Monotherapy (Part A) or in Combination With Gemcitabine and Nab-Paclitaxel (Part B) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity in Patients With Mesothelin-positive Metastatic and/or Locally Advanced Malignant Solid Tumors
- First Posted Date
- 2014-12-16
- Last Posted Date
- 2016-07-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 15
- Registration Number
- NCT02317419
Prospective Observational Study on the Management of Patients With Relapsed or Refractory Follicular Lymphoma (OLYMPE)
- First Posted Date
- 2014-12-15
- Last Posted Date
- 2016-02-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 260
- Registration Number
- NCT02316613
A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2014-12-04
- Last Posted Date
- 2017-12-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 26
- Registration Number
- NCT02308761
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
An Observational Study of Kadcyla Safety in Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2014-12-02
- Last Posted Date
- 2023-01-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 563
- Registration Number
- NCT02305641
- Locations
- 🇰🇷
Yeungnam University Medical Center; Surgical Department of Breast and Internal Secretion, Daegu, Korea, Republic of
🇰🇷Kosin University Gospel Hospital, Busan, Korea, Republic of
🇰🇷Dong-A University Hospital, Busan, Korea, Republic of
An Observational Study of Herceptin SC Safety in Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2014-12-02
- Last Posted Date
- 2020-11-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 600
- Registration Number
- NCT02305628
- Locations
- 🇰🇷
Ulsan University Hosiptal, Ulsan, Korea, Republic of
🇰🇷Hallym University Sacred Heart Hospital, Gyeonggi-do, Korea, Republic of
🇰🇷Gachon University Gil Medical Center, Incheon, Korea, Republic of